YZYinhong Zhang

Yinhong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yinhong Zhang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Baosheng Zhu

    Department of Medical Genetics, Yunnan Provincial Key Laboratory of Birth Defects and Genetic Diseases, NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China, The First People’s Hospital of Yunnan Province & The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China

    2 shared publications
  • Cidan Huang

    Neonatal Disease Screening Center, Hainan Women and Children’s Medical Center, Haikou 570206, China

    2 shared publications
  • Hui Zou

    Neonatal Disease Screening Center, Jinan Maternity and Child Health Hospital Affiliated to Shandong First Medical University, Jinan 250001, China

    2 shared publications
  • Jizhen Feng

    Department of Genetic, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang 050006, China

    2 shared publications
  • Lianshu Han

    Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute of Pediatric Research, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Xiaohua Wang

    Inner Mongolia Maternity and Child Health Care Hospital, Hohhot, China

    2 shared publications

Latest Publications

  • Open Access

    Lycorine suppresses DPP3-mediated Nrf2 signaling, thereby reducing SLC7A11 levels to trigger ferroptosis in colorectal cancer cells

    by Juan Sheng, Qixian An, Fubing Yu, Yuliang Xiao, Huifeng Ding, Lijuan Wu, Guanyu Duan, Tiantian Yangyin, Han Chen, Jia Wang, et al.


  • [Genetic screening and follow-up results in 3 001 newborns in the Yunnan region].

    by Ao-Yu Li, Bao-Sheng Zhu, Jin-Man Zhang, Ying Chan, Jun-Yue Lin, Jie Zhang, Xiao-Yan Zhou, Hong Chen, Su-Yun Li, Na Feng, et al.

    To evaluate the application value of genetic newborn screening (gNBS) in the Yunnan region. A prospective study was conducted with a random selection of 3 001 newborns born in the Yunnan region from February to December 2021. Traditional newborn screening (tNBS) was used to test biochemical indicators, and targeted next-generation sequencing was employed to screen 159 genes related to 156 diseases. Positive-screened newborns underwent validation and confirmation tests, and confirmed cases received standardized treatment and long-term follow-up. Among the 3 001 newborns, 166 (5.53%) were initially positive for genetic screening, and 1 435 (47.82%) were genetic carriers. The top ten genes with the highest variation frequency were GJB2 (21.29%), DUOX2 (7.27%), HBA (6.14%), GALC (3.63%), SLC12A3 (3.33%), HBB (3.03%), G6PD (2.94%), SLC25A13 (2.90%), PAH (2.73%), and UNC13D (2.68%). Among the initially positive newborns from tNBS and gNBS, 33 (1.10%) and 47 (1.57%) cases were confirmed, respectively. A total of 48 (1.60%) cases were confirmed using gNBS+tNBS. The receiver operating characteristic curve analysis demonstrated that the areas under the curve for tNBS, gNBS, and gNBS+tNBS in diagnosing diseases were 0.866, 0.982, and 0.968, respectively (PP<0.05). gNBS can expand the range of disease detection, and its combined use with tNBS can significantly shorten diagnosis time, enabling early intervention and treatment.

  • Open Access

    Newborn Genetic Screening Improves the Screening Efficiency for Congenital Hypothyroidism: A Prospective Multicenter Study in China

    by Liang Ye, Yinhong Zhang, Jizhen Feng, Cidan Huang, Xiaohua Wang, Lianshu Han, Yonglan Huang, Hui Zou, Baosheng Zhu, Jingkun Miao

    Newborn congenital hypothyroidism (CH) screening has been widely used worldwide. The objective of this study was to evaluate the effectiveness of applying biochemical and gene panel sequencing as screening tests for CH and to analyze the mutation spectrum of CH in China. Newborns were prospectively recruited from eight hospitals in China between February and December 2021. Clinical characteristics were collected. Second-generation sequencing was used to detect four CH-related genes, and the genetic patterns of the pathogenic genes were analyzed. We analyzed the relationship between genotype and biochemical phenotype. A total of 29,601 newborns were screened for CH. Gene panel sequencing identified 18 patients, including 10 patients affected by biochemically and genetically screened disorders and 8 patients affected by solely genetically screened disorders. The predictive positive value of genetic screening was 34.62%, which was much greater than that of biochemical screening alone (17.99%). A total of 94 cases of congenital thyroid dysfunction were confirmed by biochemical and genetic screening, including 30 CHs and 64 isolated hyperthyrotropinemia (HTT), with an incidence of 1/987 for CH and 1/463 for HTT, and a total incidence of 1/315 for hypothyroidism. The incidence rate and number of patients in Jinan were the highest, and the incidence rates in Shijiazhuang and Shanghai were the lowest. The gene mutation rate in this study was 19.1%, mainly DUOX2 mutation. The most common variant of DUOX2 was c.1588A>T(p.Lys530*). There was only a difference in sFT4 between groups with gene mutations and those without mutations. Genetic screening is a supplement to biochemical screening. Combining biochemical screening with genetic screening is useful for improving screening efficiency. The incidence of CH in China according to a multicenter study of nearly 30,000 NBS surveys was 1/315. DUOX2 gene mutations are commonly detected in these patients.


  • Open Access

    Newborn Screening for Inborn Errors of Metabolism by Next-Generation Sequencing Combined with Tandem Mass Spectrometry

    by Chengfang Tang, Lixin Li, Ting Chen, Yulin Li, Bo Zhu, Yinhong Zhang, Yifan Yin, Xiulian Liu, Cidan Huang, Jingkun Miao, et al.

    The aim of this study was to observe the outcomes of newborn screening (NBS) in a certain population by using next-generation sequencing (NGS) as a first-tier screening test combined with tandem mass spectrometry (MS/MS). We performed a multicenter study of 29,601 newborns from eight screening centers with NBS via NGS combined with MS/MS. A custom-designed panel targeting the coding region of the 142 genes of 128 inborn errors of metabolism (IEMs) was applied as a first-tier screening test, and expanded NBS using MS/MS was executed simultaneously. In total, 52 genes associated with the 38 IEMs screened by MS/MS were analyzed. The NBS performance of these two methods was analyzed and compared respectively. A total of 23 IEMs were diagnosed via NGS combined with MS/MS. The incidence of IEMs was approximately 1 in 1287. Within separate statistical analyses, the positive predictive value (PPV) for MS/MS was 5.29%, and the sensitivity was 91.3%. However, for genetic screening alone, the PPV for NGS was 70.83%, with 73.91% sensitivity. The three most common IEMs were methylmalonic academia (MMA), primary carnitine deficiency (PCD) and phenylketonuria (PKU). The five genes with the most common carrier frequencies were PAH (1:42), PRODH (1:51), MMACHC (1:52), SLC25A13 (1:55) and SLC22A5 (1:63). Our study showed that NBS combined with NGS and MS/MS improves the performance of screening methods, optimizes the process, and provides accurate diagnoses.


  • Gene mutations in children with permanent congenital hypothyroidism in Yunnan, China

    by Yanling Gong, Yinhong Zhang, Fan Liu, Baosheng Zhu, Xiaoyan Zhou, Ying Chan, Suyun Li, Li Li

    分析云南地区永久性先天性甲状腺功能减退症(CH)患儿的基因突变及其临床表型特点。 回顾性分析2016年1月至2019年1月经云南省第一人民医院诊治的40例CH患儿的临床资料,所有患儿随访至3岁,分别在患儿1、2和3岁时行格塞尔发育量表评分,评估患儿发育状况和预后。采用高通量测序检测27个已知的CH相关基因,分析基因型和临床表型之间的关系。 40例患儿中23例检出相关基因突变,突变检出率为57.5%;共检出8个基因的32种突变类型,前三位突变基因为 DUOX2、 TPO和 TSHR,突变频率分别为65.9%(29/44)、11.4%(5/44)和9.1%(4/44);17例检出 DUOX2基因突变患儿存在17种突变类型,其中p.K530*突变频次最高,占比20.7%(6/29); DUOX2杂合突变与复合杂合突变患儿的体格发育和智力发育评估差异无统计学意义( P>0.05),患儿随访至3岁均不能停药,表现为永久性CH。携带其他基因突变患儿的体格和智力发育评估也在正常范围。 云南地区永久性CH患儿 DUOX2、 TPO和 TSHR基因突变检出率较高,基因突变类型与CH患儿预后无明显相关性。